Amanda Littlewood-Evans
Overview
Explore the profile of Amanda Littlewood-Evans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kearns J, Wassmann P, Olgac U, Fichter M, Christen B, Rubic-Schneider T, et al.
Sci Transl Med
. 2023 Feb;
15(681):eabq5068.
PMID: 36724241
Immunogenicity against intravitreally administered brolucizumab has been previously described and associated with cases of severe intraocular inflammation, including retinal vasculitis/retinal vascular occlusion (RV/RO). The presence of antidrug antibodies (ADAs) in...
2.
Karle A, Wrobel M, Koepke S, Gutknecht M, Gottlieb S, Christen B, et al.
Sci Transl Med
. 2023 Feb;
15(681):eabq5241.
PMID: 36724238
In October 2019, Novartis launched brolucizumab, a single-chain variable fragment molecule targeting vascular endothelial growth factor A, for the treatment of neovascular age-related macular degeneration. In 2020, rare cases of...
3.
Hoyler T, Bannert B, Andre C, Beck D, Boulay T, Buffet D, et al.
JCI Insight
. 2022 Jul;
7(13).
PMID: 35801586
IL-1 receptor-activated kinase 1 (IRAK1) is involved in signal transduction downstream of many TLRs and the IL-1R. Its potential as a drug target for chronic inflammatory diseases is underappreciated. To...
4.
Willemsen J, Neuhoff M, Hoyler T, Noir E, Tessier C, Sarret S, et al.
Cell Rep
. 2021 Nov;
37(6):109977.
PMID: 34758308
Tumor necrosis factor (TNF) is a key driver of several inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, in which affected tissues show an interferon-stimulated gene signature....
5.
Markert C, Thoma G, Srinivas H, Bollbuck B, Luond R, Miltz W, et al.
J Med Chem
. 2021 Feb;
64(4):1889-1903.
PMID: 33592148
The cytosolic metalloenzyme leukotriene A hydrolase (LTA4H) is the final and rate-limiting enzyme in the biosynthesis of pro-inflammatory leukotriene B (LTB). Preclinical studies have validated this enzyme as an attractive...
6.
Velcicky J, Wilcken R, Cotesta S, Janser P, Schlapbach A, Wagner T, et al.
J Med Chem
. 2020 Aug;
63(17):9856-9875.
PMID: 32856916
G-protein-coupled receptor SUCNR1 (succinate receptor 1 or GPR91) senses the citric cycle intermediate succinate and is implicated in various pathological conditions such as rheumatoid arthritis, liver fibrosis, or obesity. Here,...
7.
Spieler V, Ludwig M, Dawson J, Tigani B, Littlewood-Evans A, Safina C, et al.
J Control Release
. 2020 Jul;
326:172-180.
PMID: 32653504
Anti-inflammatory cytokines are a promising class of therapeutics for treatment of rheumatoid arthritis (RA), but their use is currently limited by a rapid clearance and systemic toxicity. Interleukin-4 is a...
8.
Martin K, Junker U, Tritto E, Sutter E, Rubic-Schneider T, Morgan H, et al.
Front Immunol
. 2020 May;
11:745.
PMID: 32425939
Genetic disruption or short-term pharmacological inhibition of MALT1 protease is effective in several preclinical models of autoimmunity and B cell malignancies. Despite these protective effects, the severe reduction in regulatory...
9.
Angst D, Gessier F, Janser P, Vulpetti A, Walchli R, Beerli C, et al.
J Med Chem
. 2020 Feb;
63(10):5102-5118.
PMID: 32083858
Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent...
10.
Huppertz C, Jager B, Wieczorek G, Engelhard P, Oliver S, Bauernfeind F, et al.
Eur Respir J
. 2020 Jan;
55(3).
PMID: 31949113
Sarcoidosis is a disease characterised by granuloma formation. There is an unmet need for new treatment strategies beyond corticosteroids. The NLRP3 inflammasome pathway is expressed in innate immune cells and...